• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

    19.30 +0.48 (+2.55%)
    Streaming Delayed Price Updated: 11:05 AM EST, Mar 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 177,192
    Open 18.91
    Bid (Size) 19.16 (100)
    Ask (Size) 19.31 (200)
    Prev. Close 18.82
    Today's Range 18.11 - 19.48
    52wk Range 3.420 - 30.00
    Shares Outstanding 36,130,121
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    UroGen (URGN) Q4 2025 Earnings Call Transcript ↗
    UroGen (URGN) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q4 2025 Results Amid Strong Commercial Progress ↗
    Via Chartmill

    Performance

    YTD
    -15.0%
    -15.0%
    1 Month
    -2.0%
    -2.0%
    3 Month
    -20.8%
    -20.8%
    6 Month
    -1.2%
    -1.2%
    1 Year
    +108.2%
    +108.2%

    More News

    Read More
    News headline image
    UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗
    Via The Motley Fool
    Topics Death Regulatory Compliance
    News headline image
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen (URGN) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    UROGEN PHARMA LTD (NASDAQ:URGN) Reports Q3 2025 Earnings: Revenue Misses, Loss Per Share Beats ↗
    Via Chartmill
    News headline image
    UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at Upcoming Investor Conferences
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen (URGN) Q2 Revenue Rises 11% ↗
    Via The Motley Fool
    Topics Intellectual Property

    Frequently Asked Questions

    Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?
    Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.
    What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?
    UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?
    The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market
    What is the current price of UroGen Pharma Ltd. - Ordinary Shares?
    The current price of UroGen Pharma Ltd. - Ordinary Shares is 19.30
    When was UroGen Pharma Ltd. - Ordinary Shares last traded?
    The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 03/04/26 11:05 AM ET
    What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?
    The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 697.31M
    How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?
    UroGen Pharma Ltd. - Ordinary Shares has 697M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.